Article
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Clinical lung cancer - 1 May 2020
Del Re Marzia, Petrini Iacopo, Mazzoni Francesca, Valleggi Simona, Gianfilippo Giulia, Pozzessere Daniele, Chella Antonio, Crucitta Stefania, Rofi Eleonora, Restante Giuliana, Miccoli Mario, Garassino Marina Chiara, Danesi Romano
Abstract excerpt
BACKGROUND: Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. The EGFR T790M mutation is the most common mechanis...
Topics
- Afatinib
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Cell-Free Nucleic Acids
- Disease Progression
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Follow-Up Studies